J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase 2b …
J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push Read More